This study demonstrated that BRD4 plays a fundamental role in direct activation of tumor lineage plasticity programs and that its inhibitor AZD5153 is highly promising in effective treatment of the lethal forms of prostate cancer. The gene discussed is BRD4; the disease is Familial prostate cancer.